Form 4 for HURA TuHURA Biosciences, Inc./NV
Accepted 2022-08-03 00:00:00 ET · period of report 2022-08-01 · accession 0001493152-22-021170 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-03 | 2022-08-01 | HURA | Hoffman Robert E. | Pres, CEO, Dir | A - Grant | $0.00 | +400.1K | 455.1K | +728% | $0 |
| D | 2022-08-03 | 2022-08-01 | HURA | Hoffman Robert E. | Pres, CEO, Dir | A - Grant | $0.00 | +1.20M | 1.20M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-01 | A | A | 400,145 | $0.00 | 455,145 | D | — | — | (F1) The Reporting Person was granted 400,145 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023. |
| 2 | Derivative | Option (right to buy) | 2022-08-01 | A | A | 1,200,634 | $0.00 | 1,200,634 | D | $0.18 · — to 2022-08-02 | 1,200,634 Common Stock | (F2) The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter. |